S9. Cercetari clinice asupra efectului cefatrizin (Santatricin®) in gonoreea acuta necomplicata
Santatricin® - cefatrizina - este o cefalosporina orala de generatia a II-a, cu spectru antibacterian larg, corespunzator clasei, si indicatii variate, in infectii ORL, de cai respiratorii, ale pielii si partilor moi, precum si genito-urinare.
Studiul a fost efectuat in Clinica de Dermato-venerologie „Prof. Dr. S. Longhin" Bucuresti pe 20 bolnavi diagnosticati bacteriologic cu gonoree acuta necomplicata, cu varste cuprinse intre 14 si 40 ani.
Doza administrata a variat, in functie de raspunsul bacteriologic, intre 2 g (4 comprimate odata) si 6 g (12 comprimate administrate pe parcursul a 3 zile).
Controlul bacteriologic s-a facut inainte de tratament, la 24 ore dupa doza unica, la 3 si respectiv 7 zile dupa intreruperea terapiei.
S-a obtinut vindecarea clinica si bacteriologica dupa doza unica de 2 g in 4 cazuri (20%); restul de 16 bolnavi au necesitat continuarea tratamentului inca 2 zile (cu o doza de 2 g/zi). Controlul bacteriologic la 3 si 7 zile dupa ultima doza administrata la cei 16 pacienti a fost negativ. In concluzie, putem afirma ca Santatricin® este eficace in terapia gonoreei acute necomplicate, rezultate optime obtinandu-se dupa administrarea a 2 g/zi, timp de 3 zile.
S9. Clinical Trial on the Efficiency of Cefatrizine (Santatricin®) in Acute Non-complicated Gonorrhea
Santatricin® - cefatrizine - is on oral cephalosporin of the 2nd generation, with range of antibacterial activity, similar to other agents of its class. The indications of its use vary widely from ENT infections to infections of skin and soft tissues and also genito-urinary infections.
The study was carried out in the Dermato-venerology Clinic "Prof. Dr. S. Longhin" Bucharest, including 20 patients 14-40 years of age, with a bacteriological diagnosis of acute non-complicated gonorrhea.
The administered dose varied according to the bacteriological response, from 2 g (4 tb. given at one time, unique dose) to 6 g (12 tb. given over 3 days).
Bacteriological examinations were performed before therapy, 24 h after administering the unique dose and 7 days after the discontinuation of therapy.
Clinical and bacteriological cure was obtained after the 2 g unique dose in 20% of the patients (4 cases); the rest needed continuation of therapy for on additional 2 days (at a dose of 2 g/day).
Bacteriological examinations at 7 days after the last administered dose proved negative in all 16 patients.
In conclusion, we can assume that Santatricin® is efficient in the treatment of acute non-complicated gonorrhea, optimal results showing after administering dose of 2 g day, for a total of 3 days.